ReviewCells2020
Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Hypoxia-induced BTN3A2 promotes glioma progression and chemoresistance via AKT/SP1/RAD51-mediated DNA damage.Cell death & disease · 2026Article
- The changing immune landscape of innate-like T cells and other innate cells throughout life.Immunology and cell biology · 2026Article
- Review
- Immunological and molecular signatures of carbamazepine-induced maculopapular exanthema.Frontiers in immunology · 2026Article
- Multiomics Mendelian randomization integrating pQTL, eQTL and mQTL data revealed BTN3A2 as a potential drug target for nephrolithiasis.Scientific reports · 2025Article
- Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells.Immuno-oncology technology · 2025Article
- Mapping the extracellular molecular architecture of the pAg-signaling complex with α-Butyrophilin antibodies.Scientific reports · 2025Article
- Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.Frontiers in immunology · 2025Article
- Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy.Clinical & translational immunology · 2024Review
- Directing the migration of serum-free,Frontiers in immunology · 2024Article
- A distinct topology of BTN3A IgV and B30.2 domains controlled by juxtamembrane regions favors optimal human γδ T cell phosphoantigen sensing.Nature communications · 2023Article
- BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.International journal of molecular sciences · 2022Review
- Altered immunity to microbiota, B cell activation and depleted γδ/resident memory T cells in colorectal cancer.Cancer immunology, immunotherapy : CII · 2022Article
- Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade.Frontiers in oncology · 2022Article
- Tumor-infiltrating lymphocytes in the immunotherapy era.Cellular & molecular immunology · 2021Review
- Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens.Frontiers in immunology · 2021Article
- Gamma Delta T Cells (γδ T Cells) in Health and Disease: In Memory of Professor Wendy Havran.Cells · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapies based on in vivo stimulation, or on adoptive T cell transfer of Vγ9Vδ2 T cells, have been tested in the past decades but have failed to provide consistent clinical efficacy. New, promising concepts such as γδ Chimeric Antigen Receptor (CAR) -T cells and γδ T-cell engagers are currently under preclinical evaluation. Since the impact of factors, such as the relatively low abundance of γδ T cells within tumor tissue is still under investigation, it remains to be shown whether these effector T cells can provide significant efficacy against solid tumors. Here, we highlight key learnings from the natural role of Vγ9Vδ2 T cells in the elimination of host cells bearing intracellular bacterial agents and we translate these into the setting of tumor therapy. We discuss the availability and relevance of preclinical models as well as currently available tools and knowledge from a drug development perspective. Finally, we compare advantages and disadvantages of existing therapeutic concepts and propose a role for Vγ9Vδ2 T cells in immune-oncology next to Cluster of Differentiation (CD) 3 activating therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.